Pelthos Therapeutics Inc PTHS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2024-02-16 |
| Shares Out. | 3,480,000 |
| Website | ir.pelthos.com/ ↗ |
| Phone | 19199082422 |
| Employees | 92 |
| Revenue | $10.9M |
| Gross Profit | $9.2M |
| Net Income | -$10.2M |
| Free Cash Flow | -$35.4M |
| Total Assets | $145.4M |
| Total Liabilities | $110.3M |
| Equity | $35.1M |
About Pelthos Therapeutics Inc
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Pelthos Therapeutics Inc is a publicly traded company under the ticker symbol PTHS on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)